Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: The continued increase in prevalence of methamphetamine use in the United States has resulted in a significant increase in the number of patients entering treatment for methamphetamine use. However, no robustly efficacious pharmacologic treatment for methamphetamine use or withdrawal has been identified to date after stopping methamphetamine use. Aims: Given the association between methamphetamine withdrawal and relapse during early treatment, this study tested a controlled d-amphetamine withdrawal paradigm among methamphetamine-using individuals. Methods: Treatment-seeking adults who used methamphetamine ( N = 34; 47% female; 100% white) were enrolled in a 4-week, randomized, double-blind, placebo-controlled trial in a residential setting, in which all participants were maintained on d-amphetamine (30 mg BID) during week 1, then half were switched to placebo during weeks 2–3. All participants received placebo during week 4. Outcomes included vital signs, withdrawal, cravings for methamphetamine, mood, and cognition. Bivariate analyses tested treatment group differences on baseline demographic and outcome variables. Repeated measures models examined main and interaction effects of treatment over time. Results/Outcomes: Participants were successfully randomized and safely stabilized on d-amphetamine. Craving for methamphetamine increased during weeks 2–3 in the placebo group relative to those on d-amphetamine. Interactions with age and heart rate were noted. Conclusions/Interpretation: To our knowledge, this is the first double-blind, placebo-controlled trial measuring pharmacologic effects of abruptly stopping controlled d-amphetamine administration in adults who use methamphetamine. Results support the potential of this withdrawal paradigm to further examine the efficacy of pharmacologic agents in ameliorating methamphetamine withdrawal symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three medication studies showed significant reductions in craving ratings for MA: d-amphetamine 60mg/d for four weeks (48), combination of extended release naltrexone (380mg every 3 weeks) and bupropion (450mg q d; (49)) and rTMS (10HZ at left DPLFC, two 5-day sessions over 12 days (42)).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of interest, significant increase in heart rate for placebo over 60mg d-amphetamine were reported in week 1 of the 4-week trial of d-amphetamine (48), though otherwise the medication was tolerated well.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“heart rate elevated in placebo during week 1”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Thompson, R.G., Jr. et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Significant attenuation of craving compared to placebo group”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Thompson, R.G., Jr. et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Secondary outcome measures included Hamilton Depression (HAM-D; Hamilton, 1960) and Hamilton Anxiety (HAM-A; Hamilton, 1959) Scales, the Stroop Color Word Test (Golden, 1978), and vital signs.”
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Cochrane Database of Systematic Reviews
(2008) · Encyclopedia of Public Health · doi:10.1007/978-1-4020-5614-7_436 · Cited by 4,527
ALCOHOL HEALTH AND RESEARCH WORLD
Vejnoska, J. (1983) · Alcohol health and research world · Cited by 1,971
A review of the clinical pharmacology of methamphetamine
Cruickshank, C. C., & Dyer, K. R. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02564.x · Cited by 769
The nature, time course and severity of methamphetamine withdrawal
McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01160.x · Cited by 458 · cited 7×
“Although 87%–97% of recently-abstinent amphetamine users are thought to experience withdrawal (Cantwell and McBride, 1998; McGregor et al., 2005; Schuckit et al., 1999; Shoptaw et al., 2009) and drug withdrawal is a predictor of drug relapse (Sinha, 2011), a dearth of studies has examined the impact of potential Utili…”
InfluentialNew findings on biological factors predicting addiction relapse vulnerability
Sinha, R. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0224-0 · Cited by 401 · cited 2×
“…of recently-abstinent amphetamine users are thought to experience withdrawal (Cantwell and McBride, 1998; McGregor et al., 2005; Schuckit et al., 1999; Shoptaw et al., 2009) and drug withdrawal is a predictor of drug relapse (Sinha, 2011), a dearth of studies has examined the impact of potential”
The Methamphetamine Problem in the United States
Gonzales, R., Mooney, L., & Rawson, R. A. (2010) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.012809.103600 · Cited by 361
Research works printed but not linked: 1
- DHHS and SAMHSA (2019) Results from the 2019 National Survey on Drug Use and Health: National Findings in: Department of Health and Human Services Substance Abuse and Mental Health Services Administration Office of Applied Studies: Rockville, MD.
Cited by
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Sharafi, H., Bakouni, H., McAnulty, C., Drouin, S., Coronado‐Montoya, S., Bahremand, A., Bach, P., Ezard, N., Foll, B. L., Schütz, C. G., et al. (2023) · Addiction · doi:10.1111/add.16347 · Cited by 37
Acheson, L. S., Ezard, N., Lintzeris, N., Dunlop, A. J., Brett, J., Rodgers, C., Gill, A., Christmass, M. A., McKetin, R., Farrell, M., et al. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109692 · Cited by 23
Pro, G. C., Cantor, J., Buttram, M. E., Brown, C. C., Gu, M., Mancino, M. J., & Zaller, N. D. (2024) · Medical Care · doi:10.1097/mlr.0000000000002013 · Cited by 5
Self-citationAcheson, L. S., Clay, S., McKetin, R., Lintzeris, N., Dunlop, A. J., Brett, J., Christmass, M. A., Rodgers, C., SHOPTAW, S. J., Farrell, M., et al. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104383 · Cited by 3
Metadata
- Authors
- Thompson, R. G., Oliveto, A., Thostenson, J. D., Wilson, M. P., McGaugh, J., & Mancino, M. J.
- Affiliations
- University of Arkansas for Medical Sciences (US)
- Ouachita Behavioral Health and Wellness, Hot Springs, AR, USA
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-10-26
- Volume
- 35
- Issue
- 11
- Pages
- 1420-1430
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC10110391
- OpenAlex
- W3210879314
- Cited by
- 12
- References
- 37
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 2
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Research Resources (NCRR-RR020146)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- methamphetamine use, amphetamine withdrawal, d-amphetamine, craving, relapse prevention, heart rate, mood, cognition, residential treatment
- MeSH terms
- Adult, Central Nervous System Stimulants, Dextroamphetamine, Double-Blind Method, Female, Humans, Male, Methamphetamine, Pilot Projects, Substance Withdrawal Syndrome, Amphetamine-Related Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. https://app.cochat.ai/papers/10.1177/02698811211050563
- The paper
- Thompson, R. G., Oliveto, A., Thostenson, J. D., Wilson, M. P., McGaugh, J., & Mancino, M. J. (2021). Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211050563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.